PYC Therapeutics Names Alan Tribe Interim MD Amid CEO Exit
PYC Therapeutics announces the resignation of CEO Dr Rohan Hockings, appointing Chairman Alan Tribe as interim Managing Director while searching for a permanent replacement.
- Dr Rohan Hockings to leave by November 16, 2025
- Alan Tribe appointed interim Managing Director
- Focus on maintaining clinical program progress
- Priority on Polycystic Kidney Disease drug development
- Search underway for permanent Managing Director
Leadership Transition at PYC Therapeutics
PYC Therapeutics (ASX, PYC), a clinical-stage biotech specialising in RNA therapies, has announced a significant leadership change. Dr Rohan Hockings, the company’s CEO and Executive Director, has tendered his resignation with an expected departure date of November 16, 2025. In the interim, Chairman Alan Tribe will assume the role of Managing Director while the company initiates a search for a permanent successor.
Alan Tribe Steps Up
Mr Tribe, who has been on the PYC board since 2018, brings extensive corporate and commercial experience to his new role. Notably, he will continue to be based in the Perth office and maintain his current remuneration terms. His immediate focus will be on ensuring the company’s four clinical drug development programs remain on track, with particular emphasis on the Polycystic Kidney Disease program, which remains a strategic priority for PYC.
Maintaining Momentum in Clinical Programs
Despite the leadership change, PYC has reassured investors and stakeholders that there will be no disruption to ongoing projects. Mr Tribe has already engaged with executive and leadership teams to confirm that timelines, budgets, and performance metrics are being met. This continuity is critical given the competitive and fast-moving nature of RNA therapeutic development.
Looking Ahead
The company has committed to a robust search process for a permanent Managing Director who can lead PYC through its next growth phase. Meanwhile, Mr Tribe will also take on responsibility for investor relations and business development activities, signalling a hands-on approach during this transitional period. The terms of Mr Tribe’s executive employment have been disclosed, including a fixed annual remuneration of $80,000 and a six-month notice period.
Context in the Biotech Sector
Leadership changes in clinical-stage biotech firms often prompt market scrutiny, given the potential impact on strategic direction and operational stability. PYC’s transparent communication and clear prioritisation of its drug development pipeline suggest a measured approach to managing this transition. Investors will be watching closely for updates on the permanent appointment and progress milestones, especially in the Polycystic Kidney Disease program.
Bottom Line?
PYC’s leadership shift underscores the importance of steady stewardship as it advances critical RNA therapies.
Questions in the middle?
- Who are the leading candidates for the permanent Managing Director role?
- Will the leadership change affect timelines for key clinical milestones?
- How will investor confidence be managed during this transition?
